Analysis of tumor marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: A comparative study

Journal of Contemporary Dental Practice

Volumn 13, Issue 5, 2012, Pages 671-675

  Balan, Jude J ^a   Rao, Roopa S ^a   Premalatha, B R ^a   Patil, Shankargouda ^a  

^a M S RAMAIAH UNIVERSITY OF APPLIED SCIENCES   (India)

Author keywords

Ca 125; Elisa; Oral squamous cell carcinoma; Saliva; Tumor marker

Indexed keywords

EID: 84872407195     PISSN: None     EISSN: 15263711     Source Type: Journal    
DOI: 10.5005/jp-journals-10024-1207     Document Type: Article

References (19)

1. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009;45:309-16.
2. Streckfus CF, Bigler LR. Saliva as a diagnostic fluid. Oral Dis 2002;8:69-76.
3. Perez BH, Gipson IK. Focus on molecules: Human mucin MUC16. Exp Eye Res 2008;87(5):400-401.
4. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 (Suppl 3):274-81.
5. Rogers SN, Brown JS, Woolgar JA, Lowe D, Magennis P, Shaw RJ. Survival following primary surgery for oral cancer. Oral Oncol 2009;45:201-11.
6. Gomez I, Warnakulasuriya S, Vareta-Centelles PI, Lopez- Jornet P, Suarez-Cunqueiro M, Diz-Dios P, et al. Is early diagnosis of oral cancer a feasible objective? Who is to blame for diagnostic delay? Oral Dis 2010;16:333-42.
7. Kujan O, Glenny AM, Duxbury J. Evaluation of screening strategies for improving oral cancer mortality: A cochrane systematic review. J Dent Educ 2005;69:255-65.
8. Sankaranarayanan R, Ramadas K, Thomas G, Muwange R, Somanathan T, Mathew B. Effect of screening on oral cancer mortality in Kerala, India: A cluster randomized controlled trial. Lancet 2005;365:1927-33.
9. Haeckel R, Hanecke P. Application of saliva for drug monitoring: An in vivo model for transmembrane transport. Eur J Clin Biochem 1996;34:171-91.
10. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet 1992;23:365-79.
11. Lakshmanan I, Ponnusamy MP, Das S, Chakraborty S. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012 Feb 16;31(7):805-17.
12. Comamala M, Pinard M, Theériault C, Matte I. Downregulation of cell surface CA 125/MUC16 induces epithelial-tomesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 2011;104: 989-99.
13. Nagler R, Bahar G, et al. Concomitant analysis of salivary tumor markers. A new diagnostic tool for oral cancer. Clin Cancer Res 2006;12(13):3979-84.
14. Linkov F, Lisovich A, Yurkovetsky Z. Early detection of head and neck cancer: Development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol. Biomarkers Prev 2007;16(1):102-07.
15. Di-Xia, Chen, Schwartz, Peter E, Fan-Qin Li. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990 Apr;75(4):701-04.
16. Plante M, Wong GY, Nisselbaum JS. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer. Obstet Gynecol 1993 Jun;81(6):989-92.
17. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A. Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract 2009 Nov 1;10(6):E001-08.
18. Tay SK, Chua EK. Correlation of serum, urinary and salivary CA 125 levels in patients with adnexal masses. Ann Acad Med Singapore 1994 May;23(3):311-14.
19. Hunter VJ, Daly L, Helms M. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 1990;163:1164-67.